1. Home
  2. NAMSW

NAMSW

NewAmsterdam Pharma Company N.V. Warrant

Logo NewAmsterdam Pharma Company N.V. Warrant

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-12-2024 4:00pm EST

$
-
-
.
-
-
-
$
-
.
-
-
-
.
-
-
%

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.

Founded: N/A Country:
Netherlands
Netherlands
Employees: 29 City: NARRDEN
Market Cap: N/A IPO Year: N/A
Target Price: N/A AVG Volume (30 days): N/A
Analyst Decision: N/A Number of Analysts: N/A
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: N/A EPS Growth: N/A
52 Week Low/High: N/A Next Earning Date: N/A
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

Share on Social Networks: